Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Cancer Institute Clinical Trials Advisory Committee.
The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.
Name of Committee: National Cancer Institute Clinical Trials Advisory Committee.
Date: November 14, 2007.
Time: 8 a.m. to 5 p.m.
Agenda: Update on the progress of the implementation of the Clinical Trials Working Group.
Place: National Institutes of Health, Building 31, 31 Center Drive, Room 10, Bethesda, MD 20892.
Contact Person: Sheila A. Prindiville, MD, Director, Coordinating Center for Clinical Trials, Office of the Director, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd., Suite 507, Bethesda, MD 20892, 301-451-5048, email@example.com.
Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Start Printed Page 56366Cancer Control, National Institutes of Health, HHS)Start Signature
Dated: September 26, 2007.
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-4862 Filed 10-2-07; 8:45 am]
BILLING CODE 4140-01-M